ES | EN
A researcher in a lab coat walking toward the entrance of a glass building

Genomics for the Pharmaceutical Industry

NGS sequencing and bioinformatics analysis for R&D teams at pharmaceutical companies, biotechnology firms, and CROs, with a certified laboratory and guidance throughout the entire process.

ISO 9001Quality management, certified by AENOR
ISO 27001information security, certified by AENOR
GDPRData stored on our own infrastructure, with a Data Protection Officer
IVDlibraries and sequencing on IVD-labeled equipment

Reliable genomic data for every R&D program

We generate and analyze sequencing data from cellular models, animal models, and human samples using standardized procedures and controls,
with traceability of the versions of the bioinformatics pipelines used in each analysis.

Genomics

Exome and whole-genome sequencing to detect point mutations, indels, CNVs, and structural variants.

  • WES
  • WGS
  • Germinal
  • Somatic tumor/control

Transcriptomics

Analysis of gene expression, signaling pathways, and alternative splicing.

Single-cell RNA-Seq

Cell-by-cell expression analysis to characterize populations and responses in heterogeneous tissues.

Spatial Transcriptomics

Gene expression in its tissue context, with spatial resolution within the sample.

Análisis multiómico

Integration of data from a single cohort to stratify molecular profiles.

Bioinformática a medida

We start with the FASTQ files, tailor the analysis to each client's needs, and deliver interactive results on our Genome One Reports platform.

  1. FASTQ
  2. Quality Control
  3. Analysis
  4. Genome One Reports
Learn About Genome One Reports

Genetic evidence reduces the risk associated with the programs

Only 7.9% of candidates that advance to Phase I are ultimately approved. Human genomic data helps identify better targets and biomarkers, and an increasing number of companies are entrusting their generation to specialized partners.

~50%Of the $300 billion invested in pharmaceutical R&D in 2024, 50% went to external partners

Source: DeciBio Consulting, Pharma R&D Services Market (2025)

Probability of Success in Clinical Development

2.6×greater likelihood of success, from Phase I to approval, when the drug target has human genetic support

Sources: BIO, according to Pharma Intelligence and QLS, Clinical Development Success Rates 2011–2020 (2021), Minikel et al., *Nature* 2024

Information Quality and Security

We complete supplier questionnaires and ensure the protection of genomic data—which is considered a special category of data—at every stage of its processing.

Certifications
ISO 9001:2015 and ISO/IEC 27001:2022, certified by AENOR
External Evaluation
EMQN and GenQA Annual EQA Programs
Equipment
Libraries and Sequencing on IVD-Labeled Equipment
Data protection
GDPR and LOPDGDD, Data Processing Agreement (Art. 28), and Data Protection Officer
Security
Pseudonymization, role-based access control, network segmentation, and remote access via VPN
Traceability
Tracking of each sample and each file, from receipt to delivery

From Experimental Design to Results

  1. 1

    Design

    We'll work with you to determine the technique, the sequencing depth, and the number of replicates.

  2. 2

    Exhibitions and bookstores

    Quality control of samples and libraries using automated preparation on IVD-marked equipment.

  3. 3

    Sequencing

    Sequencing on an IVD-labeled platform with run and sample quality controls.

  4. 4

    Analysis

    Bioinformatics analysis of FASTQ files with interactive results on our Genome One Reports platform.

    Learn About Genome One Reports

Tell us about your project

We'll get back to you with a technical proposal or a call from our scientific team.

  • Response within 24 business hours
  • Free review of the experimental design
  • Option to sign an NDA before going into detail
Thank you. Prototype: The form does not submit data.
Business Communications
Terms of Use and Privacy Policy